Safety and Therapeutic Efficacy of Thymoquinone-Loaded Liposomes against Drug-Sensitive and Drug-Resistant Acinetobacter baumannii
- PMID: 34066874
- PMCID: PMC8151670
- DOI: 10.3390/pharmaceutics13050677
Safety and Therapeutic Efficacy of Thymoquinone-Loaded Liposomes against Drug-Sensitive and Drug-Resistant Acinetobacter baumannii
Abstract
In the present study, we investigated the activity of free thymoquinone (TQ) or liposomal thymoquinone (Lip-TQ) in comparison to standard antibiotic amoxicillin (AMX) against the drug-sensitive and drug-resistant Acinetobacter baumannii. A liposomal formulation of TQ was prepared and characterized and its toxicity was evaluated by analyzing the hematological, liver and kidney function parameters. TQ was effective against both drug-sensitive and drug-resistant A. baumannii as shown by the findings of drug susceptibility testing and time kill kinetics. Moreover, the therapeutic efficacy of TQ or Lip-TQ against A. baumannii was assessed by the survival rate and the bacterial load in the lung tissues of treated mice. The mice infected with drug-sensitive A. baumannii exhibited a 90% survival rate on day 30 post treatment with Lip-TQ at a dose of 10 mg/kg, whereas the mice treated with AMX (10 mg/kg) had a 100% survival rate. On the other hand, the mice infected with drug-resistant A. baumannii had a 70% survival rate in the group treated with Lip-TQ, whereas AMX was ineffective against drug-resistant A. baumannii and all the mice died within day 30 after the treatment. Moreover, Lip-TQ treatment effectively reduced the bacterial load in the lung tissues of the mice infected with the drug-sensitive and drug-resistant A. baumannii. Moreover, the blood of the mice treated with Lip-TQ had reduced levels of inflammation markers, leukocytes and neutrophils. The results of the present study suggest that Lip-TQ may prove to be an effective therapeutic formulation in the treatment of the drug-sensitive or drug-resistant A. baumannii infection as well.
Keywords: Acinetobacter baumannii; drug-resistant; inflammation; liposome; thymoquinone.
Conflict of interest statement
The authors declare no conflict of interest.
Figures











Similar articles
-
Antimicrobial, Immunomodulatory and Anti-Inflammatory Potential of Liposomal Thymoquinone: Implications in the Treatment of Bacterial Pneumonia in Immunocompromised Mice.Biomedicines. 2021 Nov 12;9(11):1673. doi: 10.3390/biomedicines9111673. Biomedicines. 2021. PMID: 34829902 Free PMC article.
-
Liposomal thymoquinone effectively combats fluconazole-resistant Candida albicans in a murine model.Int J Biol Macromol. 2015 May;76:203-8. doi: 10.1016/j.ijbiomac.2015.02.015. Epub 2015 Feb 20. Int J Biol Macromol. 2015. PMID: 25709021
-
Therapeutic potential of thymoquinone liposomes against the systemic infection of Candida albicans in diabetic mice.PLoS One. 2018 Dec 27;13(12):e0208951. doi: 10.1371/journal.pone.0208951. eCollection 2018. PLoS One. 2018. PMID: 30589842 Free PMC article.
-
Safety and Prophylactic Efficacy of Liposome-Based Vaccine against the Drug-Resistant Acinetobacter baumannii in Mice.Pharmaceutics. 2022 Jun 27;14(7):1357. doi: 10.3390/pharmaceutics14071357. Pharmaceutics. 2022. PMID: 35890253 Free PMC article.
-
Thymoquinone, an active constituent of Nigella sativa seeds, binds with bilirubin and protects mice from hyperbilirubinemia and cyclophosphamide-induced hepatotoxicity.Biochimie. 2016 Aug;127:205-13. doi: 10.1016/j.biochi.2016.05.020. Epub 2016 Jun 2. Biochimie. 2016. PMID: 27265787
Cited by
-
Safety, Stability, and Therapeutic Efficacy of Long-Circulating TQ-Incorporated Liposomes: Implication in the Treatment of Lung Cancer.Pharmaceutics. 2022 Jan 9;14(1):153. doi: 10.3390/pharmaceutics14010153. Pharmaceutics. 2022. PMID: 35057049 Free PMC article.
-
Antimicrobial, Immunomodulatory and Anti-Inflammatory Potential of Liposomal Thymoquinone: Implications in the Treatment of Bacterial Pneumonia in Immunocompromised Mice.Biomedicines. 2021 Nov 12;9(11):1673. doi: 10.3390/biomedicines9111673. Biomedicines. 2021. PMID: 34829902 Free PMC article.
-
Enhanced activity of Ellagic acid in lipid nanoparticles (EA-liposomes) against Acinetobacter baumannii in immunosuppressed mice.Saudi J Biol Sci. 2023 Aug;30(8):103707. doi: 10.1016/j.sjbs.2023.103707. Epub 2023 Jun 15. Saudi J Biol Sci. 2023. PMID: 37415860 Free PMC article.
-
Antinociceptive Action of Thymoquinone-Loaded Liposomes in an In Vivo Model of Tendinopathy.Pharmaceutics. 2023 May 17;15(5):1516. doi: 10.3390/pharmaceutics15051516. Pharmaceutics. 2023. PMID: 37242757 Free PMC article.
-
Cross-Kingdom Pathogenesis of Pantoea alfalfae CQ10: Insights from Transcriptome and Proteome Analyses.Microorganisms. 2024 Oct 30;12(11):2197. doi: 10.3390/microorganisms12112197. Microorganisms. 2024. PMID: 39597586 Free PMC article.
References
-
- World Health Organization . Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annual Report 2017. World Health Organization Regional Office for Europe; Copenhagen, Denmark: 2017.
-
- Aly M., Tayeb H.T., Al Johani S.M., Alyamani E.J., Aldughaishem F., Alabdulkarim I., Balkhy H.H. Genetic diversity of OXA-51-like genes among multidrug-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia. Eur. J. Clin. Microbiol. Infect Dis. 2014;33:1223–1228. doi: 10.1007/s10096-014-2068-0. - DOI - PubMed
-
- Lee C.R., Lee J.H., Park M., Park K.S., Bae I.K., Kim Y.B., Cha C.J., Jeong B.C., Lee S.H. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front. Cell Infect Microbiol. 2017;7:55. doi: 10.3389/fcimb.2017.00055. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Molecular Biology Databases